ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Return on Equity Industry-Neutral Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FRORHYPOTHETICAL MODEL
Since ’99
+7%
Expense Ratio
0.35%
placeholder
Holdings
298
cap-weighted
Inception
Jul 2022
placeholder
Full Sharpe
0.08
Ann. Return (LS)
1.0%
Ann. Volatility
12.7%
Max Drawdown
-58.9%
Test Sharpe ’19–26
0.60
Test FF5 α (ann.)
3.9%
vs Fama-French 5
Test FF5 α t-stat
0.86
not significant
Monthly turnover
29%
of the long leg, per rebalance
Cumulative return (LS)
7%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.60
what this fund holds
Long leg ann. return
9.9%
buyable, long-only
Long-short Sharpe
0.08
requires shorting
Bottom bucket ann. return
8.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

298 of 298 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
17.57%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
9.64%
3MRK
MERCK & CO INCHealthcare$314.90B
4.98%
4RTX
RTX CORPIndustrials$260.60B
4.12%
5TMUS
T-MOBILE US INCCommunication Services$208.25B
3.30%
6AMGN
AMGEN INCHealthcare$197.69B
3.13%
7VZ
VERIZON COMMUNICATIONS INCCommunication Services$182.01B
2.88%
8STX
SEAGATE TECHNOLOGY HOLDINGS PLCTechnology$176.62B
2.79%
9ABT
ABBOTT LABORATORIESHealthcare$175.37B
2.77%
10GILD
GILEAD SCIENCES INCHealthcare$166.72B
2.64%
11T
AT&T INCCommunication Services$151.54B
2.40%
12PFE
PFIZER INCHealthcare$142.77B
2.26%
13BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
1.96%
14VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
1.95%
15SYK
STRYKER CORPHealthcare$122.63B
1.94%
16ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
1.94%
17MDT
MEDTRONIC PLCHealthcare$106.50B
1.69%
18CMCSA
COMCAST CORPCommunication Services$84.98B
1.34%
19MMM
3M COIndustrials$83.37B
1.32%
20CL
COLGATE PALMOLIVE COConsumer Defensive$74.40B
1.18%
21HON
HONEYWELL INTERNATIONAL INCIndustrials$71.29B
1.13%
22REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
1.12%
23TDG
TRANSDIGM GROUP INCIndustrials$67.93B
1.07%
24WBD
WARNER BROS DISCOVERY INCCommunication Services$67.37B
1.07%
25BSX
BOSTON SCIENTIFIC CORPHealthcare$65.44B
1.04%
26EW
EDWARDS LIFESCIENCES CORPHealthcare$49.36B
0.78%
27HEI
HEICO CORPIndustrials$47.86B
0.76%
28IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
0.71%
29BDX
BECTON DICKINSON & COHealthcare$43.58B
0.69%
30TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
0.59%
31ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
0.57%
32ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.55%
33RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
0.53%
34ZTS
ZOETIS INCHealthcare$32.10B
0.51%
35BIIB
BIOGEN INCHealthcare$30.41B
0.48%
36DXCM
DEXCOM INCHealthcare$29.58B
0.47%
37RMD
RESMED INCHealthcare$28.86B
0.46%
38GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
0.45%
39ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
0.39%
40FOXA
FOX CORPCommunication Services$24.21B
0.38%
41FWONA
LIBERTY MEDIA CORPCommunication Services$23.53B
0.37%
42UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.36%
43ASTS
AST SPACEMOBILE INCTechnology$22.43B
0.35%
44ROKU
ROKU INCCommunication Services$21.32B
0.34%
45STE
STERIS PLCHealthcare$21.26B
0.34%
46VTRS
VIATRIS INCHealthcare$20.14B
0.32%
47ZBH
ZIMMER BIOMET HOLDINGS INCHealthcare$17.63B
0.28%
48NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.27%
49CHTR
CHARTER COMMUNICATIONS INCCommunication Services$16.16B
0.26%
50BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
0.25%
51TXT
TEXTRON INCIndustrials$15.91B
0.25%
52JAZZ
JAZZ PHARMACEUTICALS PLCHealthcare$15.53B
0.25%
53SOLV
SOLVENTUM CORPHealthcare$14.08B
0.22%
54COO
COOPER COMPANIES INCHealthcare$13.99B
0.22%
55ELAN
ELANCO ANIMAL HEALTH INCHealthcare$12.90B
0.20%
56ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.20%
57PEN
PENUMBRA INCHealthcare$12.52B
0.20%
58GDDY
GODADDY INCTechnology$12.49B
0.20%
59BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
0.18%
60CLX
CLOROX COConsumer Defensive$11.65B
0.18%
61BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
0.18%
62PODD
INSULET CORPHealthcare$11.36B
0.18%
63TECH
BIO-TECHNE CORPHealthcare$11.29B
0.18%
64KRYS
KRYSTAL BIOTECH INCHealthcare$10.46B
0.17%
65GMED
GLOBUS MEDICAL INCHealthcare$10.45B
0.17%
66SIRI
SIRIUS XM HOLDINGS INCCommunication Services$10.30B
0.16%
67GSAT
GLOBALSTAR INCCommunication Services$10.20B
0.16%
68CYTK
CYTOKINETICS INCHealthcare$9.98B
0.16%
69CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.15%
70KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
0.15%
71HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.15%
72GKOS
GLAUKOS CORPHealthcare$9.21B
0.15%
73LLYVA
LIBERTY LIVE HOLDINGS INCCommunication Services$9.09B
0.14%
74PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
0.14%
75SARO
STANDARDAERO INCIndustrials$8.89B
0.14%
76ALKS
ALKERMES PLCHealthcare$8.79B
0.14%
77TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.13%
78RGEN
REPLIGEN CORPHealthcare$8.31B
0.13%
79IBRX
IMMUNITYBIO INCHealthcare$8.04B
0.13%
80AVAV
AEROVIRONMENT INCIndustrials$7.20B
0.11%
81LQDA
LIQUIDIA CORPHealthcare$7.11B
0.11%
82LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.11%
83RIOT
RIOT PLATFORMS INCFinancial Services$6.91B
0.11%
84MSA
MSA SAFETY INCIndustrials$6.60B
0.10%
85LOAR
LOAR HOLDINGS INCIndustrials$6.55B
0.10%
86PTCT
PTC THERAPEUTICS INCHealthcare$6.52B
0.10%
87LUMN
LUMEN TECHNOLOGIES INCCommunication Services$6.47B
0.10%
88CGON
CG ONCOLOGY INCHealthcare$6.34B
0.10%
89KRMN
KARMAN HOLDINGS INCIndustrials$6.12B
0.10%
90LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
0.10%
91TFX
TELEFLEX INCHealthcare$5.96B
0.09%
92TWST
TWIST BIOSCIENCE CORPHealthcare$5.84B
0.09%
93BLCO
BAUSCH & LOMB CORPHealthcare$5.80B
0.09%
94DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
0.09%
95NXST
NEXSTAR MEDIA GROUP INCCommunication Services$5.61B
0.09%
96ORKA
ORUKA THERAPEUTICS INCHealthcare$5.59B
0.09%
97AIR
AAR CORPIndustrials$5.38B
0.09%
98TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.08%
99CHH
CHOICE HOTELS INTERNATIONAL INCConsumer Cyclical$5.09B
0.08%
100VSNT
VERSANT MEDIA GROUP INCCommunication Services$5.08B
0.08%
101KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.08%
102MMED
MINIMED GROUP INCHealthcare$4.75B
0.08%
103LIVN
LIVANOVA PLCHealthcare$4.43B
0.07%
104LBRDA
LIBERTY BROADBAND CORPCommunication Services$4.43B
0.07%
105MMSI
MERIT MEDICAL SYSTEMS INCHealthcare$4.41B
0.07%
106ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.07%
107NVST
ENVISTA HOLDINGS CORPHealthcare$4.35B
0.07%
108ICUI
ICU MEDICAL INCHealthcare$3.94B
0.06%
109TDS
TELEPHONE & DATA SYSTEMS INCCommunication Services$3.90B
0.06%
110CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.06%
111USAC
USA COMPRESSION PARTNERS LPEnergy$3.78B
0.06%
112ADPT
ADAPTIVE BIOTECHNOLOGIES CORPHealthcare$3.67B
0.06%
113IRTC
IRHYTHM HOLDINGS INCHealthcare$3.64B
0.06%
114BKD
BROOKDALE SENIOR LIVING INCHealthcare$3.58B
0.06%
115ARQT
ARCUTIS BIOTHERAPEUTICS INCHealthcare$3.56B
0.06%
116MSGE
MADISON SQUARE GARDEN ENTERTAINMENT CORPConsumer Cyclical$3.56B
0.06%
117RH
RHConsumer Cyclical$3.55B
0.06%
118OGN
ORGANON & COHealthcare$3.55B
0.06%
119HAE
HAEMONETICS CORPHealthcare$3.54B
0.06%
120LBTYA
LIBERTY GLOBAL LTDCommunication Services$3.52B
0.06%
121GPCR
STRUCTURE THERAPEUTICS INCHealthcare$3.45B
0.05%
122WRBY
WARBY PARKER INCHealthcare$3.24B
0.05%
123ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
0.05%
124IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.05%
125AD
ARRAY DIGITAL INFRASTRUCTURE INCCommunication Services$3.02B
0.05%
126MBX
MBX BIOSCIENCES INCHealthcare$2.99B
0.05%
127DKL
DELEK LOGISTICS PARTNERS LPEnergy$2.92B
0.05%
128RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.05%
129BEAM
BEAM THERAPEUTICS INCHealthcare$2.83B
0.04%
130XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.04%
131ADEA
ADEIA INCTechnology$2.80B
0.04%
132SUPN
SUPERNUS PHARMACEUTICALS INCHealthcare$2.79B
0.04%
133TRVI
TREVI THERAPEUTICS INCHealthcare$2.71B
0.04%
134GCMG
GCM GROSVENOR INCFinancial Services$2.61B
0.04%
135TARS
TARSUS PHARMACEUTICALS INCHealthcare$2.58B
0.04%
136TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
0.04%
137DCO
DUCOMMUN INCIndustrials$2.54B
0.04%
138CALX
CALIX INCTechnology$2.50B
0.04%
139ATRO
ASTRONICS CORPIndustrials$2.41B
0.04%
140VCEL
VERICEL CORPHealthcare$2.38B
0.04%
141PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.04%
142BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.04%
143LMAT
LEMAITRE VASCULAR INCHealthcare$2.32B
0.04%
144MLYS
MINERALYS THERAPEUTICS INCHealthcare$2.23B
0.04%
145SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.04%
146HTFL
HEARTFLOW INCHealthcare$2.15B
0.03%
147AXGN
AXOGEN INCHealthcare$2.12B
0.03%
148AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.03%
149RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.03%
150ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.03%
151ZD
ZIFF DAVIS INCCommunication Services$1.99B
0.03%
152PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.03%
153ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.03%
154URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.03%
155ATEX
ANTERIX INCCommunication Services$1.96B
0.03%
156HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.03%
157CPRI
CAPRI HOLDINGS LTDConsumer Cyclical$1.89B
0.03%
158UFPT
UFP TECHNOLOGIES INCHealthcare$1.87B
0.03%
159NVCR
NOVOCURE LTDHealthcare$1.84B
0.03%
160SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.03%
161ANIP
ANI PHARMACEUTICALS INCHealthcare$1.80B
0.03%
162IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.03%
163ATRC
ATRICURE INCHealthcare$1.77B
0.03%
164BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.03%
165ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.03%
166EYE
NATIONAL VISION HOLDINGS INCConsumer Cyclical$1.66B
0.03%
167INVA
INNOVIVA INCHealthcare$1.60B
0.03%
168IDT
IDT CORPCommunication Services$1.57B
0.02%
169XERS
XERIS BIOPHARMA HOLDINGS INCHealthcare$1.52B
0.02%
170SEPN
SEPTERNA INCHealthcare$1.51B
0.02%
171BRUN
BOOST RUN INCTechnology$1.50B
0.02%
172IART
INTEGRA LIFESCIENCES HOLDINGS CORPHealthcare$1.50B
0.02%
173LILA
LIBERTY LATIN AMERICA LTDCommunication Services$1.48B
0.02%
174INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.02%
175AIP
ARTERIS INCTechnology$1.43B
0.02%
176KMTS
KESTRA MEDICAL TECHNOLOGIES LTDHealthcare$1.43B
0.02%
177BLFS
BIOLIFE SOLUTIONS INCHealthcare$1.42B
0.02%
178PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.02%
179NVAX
NOVAVAX INCHealthcare$1.35B
0.02%
180PBT
PERMIAN BASIN ROYALTY TRUSTEnergy$1.32B
0.02%
181STAA
STAAR SURGICAL COHealthcare$1.32B
0.02%
182CNMD
CONMED CORPHealthcare$1.30B
0.02%
183XNCR
XENCOR INCHealthcare$1.30B
0.02%
184CDRE
CADRE HOLDINGS INCIndustrials$1.24B
0.02%
185IRMD
IRADIMED CORPHealthcare$1.24B
0.02%
186AORT
ARTIVION INCHealthcare$1.22B
0.02%
187DRTS
ALPHA TAU MEDICAL LTDHealthcare$1.19B
0.02%
188TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.02%
189COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.02%
190AVNS
AVANOS MEDICAL INCHealthcare$1.17B
0.02%
191ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.02%
192MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.02%
193SECZ
SECURITIZE CORPTechnology$1.11B
0.02%
194RHLD
RESOLUTE HOLDINGS MANAGEMENT INCIndustrials$1.10B
0.02%
195PRCT
PROCEPT BIOROBOTICS CORPHealthcare$1.09B
0.02%
196NMAX
NEWSMAX INCCommunication Services$1.08B
0.02%
197GRPN
GROUPON INCCommunication Services$1.06B
0.02%
198AEVA
AEVA TECHNOLOGIES INCConsumer Cyclical$1.05B
0.02%
199PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.02%
200BVS
BIOVENTUS INCHealthcare$1.01B
0.02%
201SBGI
SINCLAIR INCCommunication Services$997M
0.02%
202JANX
JANUX THERAPEUTICS INCHealthcare$992M
0.02%
203EVC
ENTRAVISION COMMUNICATIONS CORPCommunication Services$984M
0.02%
204VOR
VOR BIOPHARMA INCHealthcare$980M
0.02%
205GLIBA
GCI LIBERTY INCCommunication Services$881M
0.01%
206TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.01%
207PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.01%
208AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.01%
209CYRX
CRYOPORT INCIndustrials$832M
0.01%
210AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.01%
211SKYH
SKY HARBOUR GROUP CORPIndustrials$797M
0.01%
212SIBN
SI-BONE INCHealthcare$771M
0.01%
213BBNX
BETA BIONICS INCHealthcare$771M
0.01%
214ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.01%
215RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.01%
216MNPR
MONOPAR THERAPEUTICSHealthcare$744M
0.01%
217CBLL
CERIBELL INCHealthcare$710M
0.01%
218CCSI
CONSENSUS CLOUD SOLUTIONS INCTechnology$689M
0.01%
219PKE
PARK AEROSPACE CORPIndustrials$677M
0.01%
220CRMD
CORMEDIX INCHealthcare$661M
0.01%
221TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.01%
222SHEN
SHENANDOAH TELECOMMUNICATIONS COCommunication Services$630M
0.01%
223FAC
FACTORIAL ENERGY INCIndustrials$610M
0.01%
224CEPF
CANTOR EQUITY PARTNERS IV INCIndustrials$596M
0.01%
225GYRE
GYRE THERAPEUTICS INCHealthcare$587M
0.01%
226ANGO
ANGIODYNAMICS INCHealthcare$558M
0.01%
227CCOI
COGENT COMMUNICATIONS HOLDINGS INCCommunication Services$549M
0.01%
228NPCE
NEUROPACE INCHealthcare$548M
0.01%
229CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
0.01%
230XOMA
XOMA ROYALTY CORPHealthcare$504M
0.01%
231KIDS
ORTHOPEDIATRICS CORPHealthcare$494M
0.01%
232SPIR
SPIRE GLOBAL INCIndustrials$488M
0.01%
233OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
0.01%
234AMCX
AMC GLOBAL MEDIA INCCommunication Services$461M
0.01%
235TMS
TMS INTERNATIONAL CORPBasic Materials$451M
0.01%
236SI
SHOULDER INNOVATIONS INCHealthcare$448M
0.01%
237DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.01%
238PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.01%
239ASMB
ASSEMBLY BIOSCIENCES INCHealthcare$426M
0.01%
240BCAR
D BORAL ARC ACQUISITION I CORPIndustrials$420M
0.01%
241USNA
USANA HEALTH SCIENCES INCConsumer Defensive$403M
0.01%
242ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.01%
243EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.01%
244STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.01%
245EOLS
EVOLUS INCHealthcare$377M
0.01%
246CEPT
CANTOR EQUITY PARTNERS II INCIndustrials$376M
0.01%
247NATR
NATURES SUNSHINE PRODUCTS INCConsumer Defensive$359M
0.01%
248ATNI
ATN INTERNATIONAL INCCommunication Services$356M
0.01%
249ELMD
ELECTROMED INCHealthcare$349M
0.01%
250CV
CAPSOVISION INCHealthcare$335M
0.01%
251CEPV
CANTOR EQUITY PARTNERS V INCIndustrials$332M
0.01%
252ALDF
ALDEL FINANCIAL II INCIndustrials$320M
0.01%
253CARL
CARLSMED INCHealthcare$317M
0.01%
254JACS
JACKSON ACQUISITION CO IIIndustrials$317M
0.01%
255FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.00%
256TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.00%
257SGHT
SIGHT SCIENCES INCHealthcare$274M
0.00%
258QTTB
Q32 BIO INCHealthcare$255M
0.00%
259SRZN
SURROZEN INCHealthcare$255M
0.00%
260VNME
VENDOME ACQUISITION CORP IIndustrials$254M
0.00%
261CXDO
CREXENDO INCCommunication Services$248M
0.00%
262RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.00%
263RXST
RXSIGHT INCHealthcare$230M
0.00%
264RDNW
RIDENOW GROUP INCConsumer Cyclical$229M
0.00%
265CABO
CABLE ONE INCCommunication Services$223M
0.00%
266SPOK
SPOK HOLDINGS INCHealthcare$222M
0.00%
267UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.00%
268KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.00%
269KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.00%
270AGEN
AGENUS INCHealthcare$209M
0.00%
271AIRO
AIRO GROUP HOLDINGS INCIndustrials$205M
0.00%
272ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.00%
273PDEX
PRO DEX INCHealthcare$183M
0.00%
274INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
275INGN
INOGEN INCHealthcare$178M
0.00%
276RANG
RANGE CAPITAL ACQUISITION CORPIndustrials$171M
0.00%
277NMP
NMP ACQUISITION CORPIndustrials$164M
0.00%
278KORE
KORE GROUP HOLDINGS INCCommunication Services$163M
0.00%
279OWLT
OWLET INCHealthcare$162M
0.00%
280RCEL
AVITA MEDICAL INCHealthcare$157M
0.00%
281SIF
SIFCO INDUSTRIES INCIndustrials$141M
0.00%
282VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.00%
283TSQ
TOWNSQUARE MEDIA INCCommunication Services$119M
0.00%
284LAKE
LAKELAND INDUSTRIES INCConsumer Cyclical$113M
0.00%
285FTLF
FITLIFE BRANDS INCConsumer Defensive$104M
0.00%
286ICCC
IMMUCELL CORPHealthcare$101M
0.00%
287RLYB
RALLYBIO CORPHealthcare$87M
0.00%
288FGMC
FG MERGER II CORPIndustrials$86M
0.00%
289LFVN
LIFEVANTAGE CORPConsumer Defensive$78M
0.00%
290ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
291CLNN
CLENE INCHealthcare$76M
0.00%
292AIRT
AIR T INCIndustrials$73M
0.00%
293SCLX
SCILEX HOLDING COHealthcare$72M
0.00%
294SKIL
SKILLSOFT CORPConsumer Defensive$58M
0.00%
295SGA
SAGA COMMUNICATIONS INCCommunication Services$58M
0.00%
296INKT
MINK THERAPEUTICS INCHealthcare$53M
0.00%
297APT
ALPHA PRO TECH LTDBasic Materials$53M
0.00%
298BKHA
BLACK HAWK ACQUISITION CORPIndustrials$50M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $6.32T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

9 sectors
Healthcare
71.5%
Communication Services
13.5%
Industrials
9.5%
Technology
3.5%
Consumer Defensive
1.4%
Consumer Cyclical
0.3%
Financial Services
0.2%
Energy
0.1%
Basic Materials
0.0%

Portfolio Style

Size × value map of the long-leg book

298 classified
Value
Blend
Growth
Large
Mid
Small
12%12
35%30
46%43
1%22
1%27
2%46
<1%21
<1%28
<1%19

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 68% toward Growth. +3% unclassified (50 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt98% → Large
SmallLarge
Value ↔ growth tilt68% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 298 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
2
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    58.4%
    Margin
    -33.4%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 298 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.9-1.4)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
12.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.27x
within
parametric
1.04x
within
cornish fisher
1.06x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 22%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1996
Entirely since publication
All 331 months of our record post-date the 1996 paper.
Sharpe 0.081.0% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-0.91
Sharpe, January 2000 – December 2002
January 1999July 2026
Median Sharpe
0.05
Dispersion
0.78
Best window
2.10

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.26.4%5.8%
3 yearsp.a.18.7%1.4%
5 yearsp.a.18.2%12.8%
10 yearsp.a.16.3%4.0%
Since inceptionp.a.8.9%0.2%
Calendar years
YearLong legLong-short
20267 mo14.8%3.7%
20257.9%-15.2%
202428.8%13.7%
202341.0%24.4%
2022-6.9%30.7%
202130.5%21.9%
202015.8%-16.7%
201929.1%0.7%
2018-7.1%-3.8%
201720.1%3.3%
20169.2%-15.1%
20157.0%14.0%
201418.4%29.0%
201336.1%5.0%
201219.1%1.3%
20115.0%1.3%
201013.6%-6.6%
200924.4%-13.2%
2008-27.7%16.1%
200711.6%7.7%
200611.8%-6.0%
20053.1%-6.9%
200410.8%-0.3%
200327.2%-5.0%
2002-28.7%-1.5%
2001-13.5%-17.7%
2000-32.2%-30.4%
199926.3%1.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FROR
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.35% (placeholder)
Inception2022-07-26 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$6.32T

Methodology

The Foundry Return on Equity Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Return on Equity signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.